Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Chicago
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed or refractory acute myelogenous or lymphoid leukemia
Chronic myelogenous leukemia in accelerated phase or blast-crisis
Chronic myelogenous leukemia in second or subsequent chronic phase
Recurrent or refractory malignant lymphoma or Hodgkin's disease
Multiple myeloma at high risk for disease recurrence
Chronic lymphocytic leukemia, relapsed or with poor prognostic features
Other Myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis) with poor prognostic features
Myelodysplastic syndromes (including PNH) with \> 5% blasts
Zubroid performance status \< 2 (See Appendix B)
Life expectancy is not severely limited by concomitant illness
Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol
Calculated Creatinine Clearance \> 50 ml/min
Serum bilirubin 2.0 mg/dl, SGPT \< 3x upper limit of normal
No evidence of chronic active hepatitis or cirrhosis
